Ranibizumab biosimilar by Generium for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval

Ranibizumab biosimilar is under clinical development by Generium and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase III drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ranibizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ranibizumab biosimilar overview

Ranibizumab biosimilar is under development for the treatment of neovascular (wet) age-related macular degeneration. The drug candidate is administered by intravitreal and intraocular route. It acts by targeting vascular endothelial growth factor A (VEGFA). It was also under development for proliferative diabetic retinopathy (PDR).

Generium overview

Generium is a pharmaceutical company developing novel biological drugs for the treatment of orphan diseases. Generium is headquartered in Moscow, Russia.

For a complete picture of Ranibizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.